Posted by Michael Wonder on 07 Jun 2018
Intra-Cellular Therapies initiates rolling submission of new drug application for lumateperone for treatment of schizophrenia
6 June 2018 - Intra-Cellular Therapies today announced the initiation of a rolling submission of its new drug application with the U.S. FDA for lumateperone for the treatment of schizophrenia.
The Company plans to complete this submission in mid-2018.
In 2017 the FDA granted fast track designation for lumateperone for the treatment of schizophrenia.
